UK's Second Ebola Vaccine Ready For Testing

The video discusses a trial for the UK's second Ebola vaccine, involving 87 volunteers. It highlights the trial's double dose nature and the small risks involved. The video also covers global efforts in developing Ebola vaccines, with candidates in the UK, Russia, China, and the US. The World Health Organization emphasizes the benefits of competition in vaccine development, potentially leading to better prices and improved epidemic responses. The trial is part-funded by the EU and is set for fast-tracked testing in Africa.

What is the nature of the trial that the volunteer is participating in?

• A single dose trial

• An observational study

• A double dose trial

• A placebo-controlled trial

Which countries are mentioned as having Ebola vaccines in development?

• UK, France, Germany, and US

• UK, Russia, China, and US

• Russia, China, India, and Brazil

• US, Canada, Australia, and Japan

What does the World Health Organization suggest about having multiple Ebola vaccines?

• It will lead to higher prices for African countries

• It will result in better prices and improved epidemic response

• It will ensure that all vaccines are effective

• It will slow down the development process

What is the significance of the trial being part-funded by the EU?

• It enables fast-tracking for testing in Africa

• It guarantees the vaccine's success

• It ensures the trial is conducted in multiple countries

• It allows for testing in Europe only

Why is it important to continue efforts against Ebola despite the slowed outbreak?

• To ensure the virus is completely eradicated

• To develop vaccines for other diseases

• To reduce the cost of vaccines

• To increase the number of volunteers